Webinar Webinar

Alzheimer’s Disease vs Multiple Sclerosis Drug Development: Similarities, Differences & New Perspectives

April 23, 2024



While Alzheimer’s Disease and Multiple Sclerosis are both neurological disorders they differ in disease mechanisms, trial objectives, patient populations, and outcomes used in clinical trials.  Lessons shared in the drug development journeys of both diseases can propel novel approaches leading to more effective and successful clinical trials in the quest for new treatments and better patient outcomes.

Learning from the experience of Multiple Sclerosis trials, Alzheimer’s trials can benefit from improved trial design, patient stratifications, outcome assessments, and incorporation of innovative methodologies.

In this webinar, distinguished physicians, experienced scientists, and clinical development experts, from Multiple Sclerosis and Alzheimer’s will discuss the main development challenges and how they were overcome in each respectively. This is the first-ever webinar discussing the AD vs. MS world perspective with top clinical research experts and disease area specialists.

Topics covered will include:

  • Disease pathology and lessons learned from repurposing drugs in MS and AD
  • The key factors to improve patient recruitment and patient retention.
  • Supportive regulatory and patient advocacy environment for effective clinical trial design
  • Benefit vs. risk mindset of the healthcare provider and patients in MS and AD



Andreas Lysandropoulos, M.D., Ph.D.

Senior Vice President, Global Therapeutic Area Head, Neuroscience

Sharon Cohen, MD, FRCPC

Behavioral Neurologist, Founder, Medical Director, Toronto Memory Program

Tjalf Ziemssen, MD

University Professor of Clinical Neuroscience